$1.62
Pacific Biosciences of California
Performance
Dividends
-18.59%
1W
1M
YTD
1Y
3Y
8/36
Growth Score
12/36
Dividend Score
Valuation
PE Ratio
-0.73
PS Ratio
3.19
RSI
-
PEG Ratio
-0.12
PRG Ratio
-0.02
0
PDG Ratio
0
Growth
56%-23%1%19%
2%-1%339%335%
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
Rule of 40
16.9%
Gross Margin
16.17%
3
Current Ratio
6.68
Return on Assets
-76.41%
0
Return on Equity
-170.4%
0
Return on inv. Capital
-99.27%
Institutional Holder
306.765.4770274.961.113
2152257
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 154.01M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -309.85M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 37.28M
2018
2019
2020
2021
2022
2023
2024
6
Events
PACB
Pacific Biosciences of California
in 462 days
after market close
Earnings per Share is expected with - and revenue with - .
PACB
Pacific Biosciences of California
in 370 days
after market close
Earnings per Share is expected with - and revenue with - .
PACB
Pacific Biosciences of California
in 252 days
after market close
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Medical - Devices
IPO Date
27.10.2010
MaketCap
486.14M
Country
US
CEO
Christian O. Henry
Description
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Updated 23.07.2025